搜尋
ADC Therapeutics SA
ADCT添加自選
1.070USD
-0.040-3.60%
收盤 09-11 16:00（美東）
135.08M總市值
虧損本益比TTM
盤後交易 19:00 (美東)1.070USD+0.005+0.47%
盤後交易 19:00 (美東)關於 ADC Therapeutics SA 公司
ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.
ADC Therapeutics SA 簡介
公司代碼ADCT
公司名稱ADC Therapeutics SA
上市日期May 15, 2020
CEOMallik (Ameet)
員工數量263
證券類型Ordinary Share
年結日May 15
公司地址Biopole
城市EPALINGES
上市交易所NASDAQ OMX NASDAQ Basic NYSE
國家Switzerland
郵編1066
電話41216530200
網址https://adctherapeutics.com/
公司代碼ADCT
上市日期May 15, 2020
CEOMallik (Ameet)
ADC Therapeutics SA公司高管
名稱
名稱/職務
職務
持股
持股變動
Mr. Ameet Mallik
Mr. Ameet Mallik
Chief Executive Officer, Director
Chief Executive Officer, Director
3.02M
+22.35%
Mr. Ameet Mallik
Mr. Ameet Mallik
Chief Executive Officer, Director
Chief Executive Officer, Director
3.02M
+22.35%
Mr. Ron R. Squarer
Mr. Ron R. Squarer
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
1.61M
+1.85%
Mr. Ron R. Squarer
Mr. Ron R. Squarer
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
1.61M
+1.85%
Dr. Mohamed Zaki, M.D., Ph.D.
Dr. Mohamed Zaki, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
1.16M
+18.47%
Dr. Mohamed Zaki, M.D., Ph.D.
Dr. Mohamed Zaki, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
1.16M
+18.47%
Mr. Jose (Pepe) Carmona
Mr. Jose (Pepe) Carmona
Chief Financial Officer
Chief Financial Officer
899.39K
+22.65%
Mr. Jose (Pepe) Carmona
Mr. Jose (Pepe) Carmona
Chief Financial Officer
Chief Financial Officer
899.39K
+22.65%
Mr. Peter J. Graham
Mr. Peter J. Graham
Chief Legal and Compliance Officer and Secretary
Chief Legal and Compliance Officer and Secretary
802.67K
+27.55%
Mr. Peter J. Graham
Mr. Peter J. Graham
Chief Legal and Compliance Officer and Secretary
Chief Legal and Compliance Officer and Secretary
802.67K
+27.55%
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Ameet Mallik
Mr. Ameet Mallik
Chief Executive Officer, Director
Chief Executive Officer, Director
3.02M
+22.35%
Mr. Ameet Mallik
Mr. Ameet Mallik
Chief Executive Officer, Director
Chief Executive Officer, Director
3.02M
+22.35%
Mr. Ron R. Squarer
Mr. Ron R. Squarer
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
1.61M
+1.85%
Mr. Ron R. Squarer
Mr. Ron R. Squarer
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
1.61M
+1.85%
Dr. Mohamed Zaki, M.D., Ph.D.
Dr. Mohamed Zaki, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
1.16M
+18.47%
Dr. Mohamed Zaki, M.D., Ph.D.
Dr. Mohamed Zaki, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
1.16M
+18.47%
常見問題
ADC Therapeutics SA的前五大股東是誰？
ADC Therapeutics SA的前五大股東如下：Mr. Ameet Mallik
有多少機構持有ADC Therapeutics SA(ADCT)的股份？
截至2026Q1，共有205家機構持有ADC Therapeutics SA的股份，合計持有的股份價值約為87.78M，占公司總股份的69.09% 。與2025Q4相比，機構持股有所增加，增幅為-1768527.00。
哪個業務部門對ADC Therapeutics SA的收入貢獻最大？
在2026Q1，Product業務部門對ADC Therapeutics SA的收入貢獻最大，創收18.63M，占總收入的96.81% 。